TipRanks on MSN
Clarity wins FDA backing for phase III trial of Cu-64 SARTATE in neuroendocrine tumours
Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals has secured positive guidance from the US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results